COVID-19: Males over 50 with chronic diseases at higher death risk
New York: Researchers have found that males over 50 with non-communicable chronic diseases such as hypertension, diabetes and coronary heart disease are at greater risk of death from coronavirus (COVID-19).
Published in the American Journal of Respiratory and Critical Care Medicine, the study identified the most common characteristics of 85 COVID-19 patients who died in Wuhan, China in the early stages of the coronavirus pandemic.
According to the study, researchers from China and the US report on an analysis of the electronic health records of patients with COVID-19 who died despite treatment at two hospitals in Wuhan: Hanan Hospital and Wuhan Union Hospital between January 9 and February 15, 2020.
“The greatest number of deaths in our cohort were in males over 50 with non-communicable chronic diseases. We hope that this study conveys the seriousness of COVID-19 and emphasises the risk groups of males over 50 with chronic comorbid conditions including hypertension (high blood pressure), coronary heart disease and diabetes,” said study researchers.
The researchers examined the medical records of 85 patients who had died and recorded information on their medical histories, exposures to coronavirus, additional chronic diseases they had (comorbidities), symptoms, laboratory findings, CT scan results and clinical management. Statistical analyses were then done.
The median age of these patients was 65.8, and 72.9 per cent were men. Their most common symptoms were fever, shortness of breath (dyspnea) and fatigue.
Hypertension, diabetes and coronary heart disease were the most common comorbidities.
A little over 80.0 per cent of patients had very low counts of eosinophils (cells that are reduced in severe respiratory infections) on admission. Complications included respiratory failure, shock, acute respiratory distress syndrome (ARDS) and cardiac arrhythmia, among others.
Most patients received antibiotics, antivirals and glucocorticoids (types of steroids). Some were given intravenous immunoglobulin or interferon-alpha-2b.
“The effectiveness of medications such as antivirals or immunosuppressive agents against COVID-19 is not completely known. Perhaps our most significant observation is that while respiratory symptoms may not develop until a week after presentation, once they do there can be a rapid decline, as indicated by the short duration between time of admission and death (6.35 days on average) in our study,” the researchers noted.
Based on their findings, eosinophilopenia – abnormally low levels of eosinophils in the blood – may indicate a poor prognosis. The scientists also noted that the early onset of shortness of breath may be used as an observational symptom for COVID-19 symptoms.
In addition, they noted that a combination of antimicrobial drugs (antivirals, antibiotics) did not significantly help these patients. The majority of patients studied died from multiple organ failure.
“Our study, which investigated patients from Wuhan, China who died in the early phases of this pandemic, identified certain characteristics. As the disease has spread to other regions, the observations from these areas may be the same, or different,” the study authors wrote.
“Genetics may play a role in the response to the infection, and the course of the pandemic may change as the virus mutates as well. Since this is a new pandemic that is constantly shifting, we think the medical community needs to keep an open mind as more and more studies are conducted,” they added.